Quantum Genesis AI Clarifies Research Affiliations and Intellectual Property Rights

Quantum Genesis AI Corp. (OTC: QGAI) has released a statement aimed at clarifying the relationship between its research activities and those of Quantumzyme LLP, a separate entity based in Bengaluru, India. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate, but noted that certain prior press releases from November 2025 and February 2026 referenced scientific publications that incorrectly implied a closer connection.

The clarification stems from the need to distinguish the company from Quantumzyme LLP, especially regarding intellectual property rights. The company stated that under an Asset Purchase Agreement dated February 21, 2023, its CEO Naveen Kulkarni transferred to Quantum Genesis AI certain intellectual property, know-how, and methodologies related to its core enzyme engineering and biocatalysis business. A subsequent confirmatory assignment was filed in April 2026, as disclosed in the company's Current Report on Form 8-K.

The company believes that research activities conducted by Kulkarni, whether directly or through Quantumzyme LLP, that are based on or derived from the transferred technology platform fall within the scope of the rights transferred to Quantum Genesis AI. This includes scientific publications that identified Quantumzyme LLP at the time of submission but are related to the company's core field.

For more information, the company directs readers to its website at www.qgaicorp.com and its profile on www.otcmarkets.com/stock/QGAI.